Immunome, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immunome, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $161.75M, a 24.91% decline year-over-year.
- Immunome, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $215.41M, a 97370.59% increase year-over-year.
- Immunome, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00.
- Immunome, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $0.00.
- Immunome, Inc. stock issued during period, value, new issues for fiscal 2023 was $221.00K.
- Immunome, Inc. stock issued during period, value, new issues for fiscal 2020 was $38.74M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-03-31 | $161.75M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $215.41M 10-Q · filed 2025-08-06 | $215.41M derived: sum of 4 quarters · filed 2025-08-06 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $221.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | |
| 2023-03-31 | $221.00K 10-Q · filed 2024-11-13 | |
| 2020-12-31 | $38.74M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |